CoChat

Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer

Open access
Henneman, Linda, van Miltenburg, Martine H., Michalak, Ewa M., Braumuller, Tanya M., Jaspers, Janneke E., Drenth, Anne Paulien, de Korte-Grimmerink, Renske, Gogola, Ewa, Szuhai, Karoly, Schlicker, Andreas, Bin Ali, Rahmen, Pritchard, Colin, Huijbers, Ivo J., Berns, Anton, Rottenberg, Sven, Jonkers, Jos · 2015 · Proceedings of the National Academy of Sciences
Cited by 126

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Significance: Poly(ADP-ribose) polymerase (PARP) inhibitors hold promise for patients with breast cancer 1 ( BRCA1 )-associatated cancers but are anticipated to give rise to resistance. We show that mouse mammary tumors resembling BRCA1-associated metaplastic breast carcinoma display intrinsic resistance to the PARP inhibitor olaparib as a result of increased P-glycoprotein drug efflux transporter expression. These findings may have implications for ongoing clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1500223112

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 126

Metadata

Authors
Henneman, L., van Miltenburg, M. H., Michalak, E. M., Braumuller, T. M., Jaspers, J. E., Drenth, A. P., de Korte-Grimmerink, R., Gogola, E., Szuhai, K., Schlicker, A., Bin Ali, R., Pritchard, C., Huijbers, I. J., Berns, A., Rottenberg, S., & Jonkers, J.
Venue
Proceedings of the National Academy of Sciences
Published
2015-06-22
Volume
112
Issue
27
Pages
8409-8414
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W801856368
Cited by
126
References
3
FWCI
4.68
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. https://app.cochat.ai/papers/10.1073/pnas.1500223112
The paper
Henneman, L., van Miltenburg, M. H., Michalak, E. M., Braumuller, T. M., Jaspers, J. E., Drenth, A. P., de Korte-Grimmerink, R., Gogola, E., Szuhai, K., Schlicker, A., Bin Ali, R., Pritchard, C., Huijbers, I. J., Berns, A., Rottenberg, S., & Jonkers, J. (2015). Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1500223112

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.